logo
Plus   Neg
Share
Email

Endo: Novitium Pharma Gets FDA Approval For Generic Equivalent Of Orfadin

Endo International plc (ENDP) said Novitium Pharma, a partner of Endo's subsidiary, has received approval from the FDA for a generic equivalent of Swedish Orphan Biovitrum's Orfadin. The Nitisinone capsules are used to treat patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Endo's operating company, Par Pharmaceutical Inc., plans to sell the product through specialty pharmacies beginning September.

Shares of Endo International plc were up more than 4 percent in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Monsanto on Thursday pleaded guilty to illegally using a banned pesticide known as Penncap-M on research crops at one of its facilities on the Hawaiian island of Maui. The agro-chemicals company will pay $10 million for charges that it unlawfully stored the banned pesticide, which had to be managed as an acute hazardous waste. The banned pesticide is specifically methyl parathion. Anti-aging skin care products, beauty serum ingredients and essential oils provider Resurrectionbeauty issued a recall for about 270 units of wintergreen essential oil due to risk of poisoning for young children if they swallow it. However, the company has not received reports of any incidents or injuries so far. The product contains the substance methyl salicylate. Microsoft has delayed the worldwide launch of its Surface Earbuds till Spring 2020. The $249 wireless earbuds were originally expected to launch this year. The delay is a setback in Microsoft's attempt to compete with Apple's latest earbuds, AirPods Pro, which has a new design and features active noise cancellation.
RELATED NEWS
Follow RTT
>